Speaking at ObesityWeek 2026 on Nov. 16, investigators of the LEAP trial shared results providing some of the strongest evidence from a randomized trial to date that long-term phentermine therapy can achieve clinically meaningful weight reduction while maintaining a favorable safety profile.
The results of the two-year study offer clinicians much-needed data on the 67-year-old medicine, one of the most frequently prescribed obesity medications in clinical practice.
The presentation team also emphasized the study population that was reflective of patient populations in primary care, highlighting outcomes that clinicians can realistically expect in routine practice through the use of a drug whose weight-reduction efficacy does not rival that of newer incretin–based therapies, but remains clinically meaningful, particularly given its low cost and accessibility.

The Prominence of Phentermine
Opening the symposium LEAP Trial: Long-Term Effectiveness of the Obesity Medication Phentermine, Jamy Ard, MD, FTOS, professor in the Department of Epidemiology and Prevention at the Wake Forest University School of Medicine, provided the historical and scientific rationale for the study. LEAP was developed to address longstanding evidence gaps surrounding phentermine, the most widely prescribed obesity medication in the United States.
Although phentermine was approved in 1959 and accounted for roughly half of obesity medication prescriptions in 2024, it has never been evaluated in an adequately powered randomized trial for long-term monotherapy.
“The most-used obesity medication in the United States is the one we know least about,” Dr. Ard said.
Phentermine was specifically engineered as an alternative to amphetamine. Its Schedule IV classification and short-term labeling emerged from concerns about abuse potential during an era when obesity was not viewed as a chronic disease requiring ongoing treatment. Dr. Ard argued that current clinical practice has outpaced the evidence base.
Dr. Ard also highlighted observational data from nearly 14,000 adults suggesting that continuous long-term use was associated with greater weight reduction, no additional cardiovascular events, and improvements in blood pressure compared with short-term use. These findings helped establish the rationale for the LEAP study, which was designed to answer three key questions: whether phentermine produces durable weight loss, what its cardiometabolic effects are, and whether it can be used safely over the long term.
Dr. Ard emphasized the significance of the trial’s findings regardless of outcome.
“Either way, the answer changes practice,” he said.
LEAP Design and Methodology

Nicholas Pajewski, PhD, a professor biostatistics and data science at Wake Forest University School of Medicine and Advocate Health, presented the design and methodology for LEAP, the Long-term Effectiveness of the Anti-obesity Medication Phentermine Trial, a large Phase IV randomized, double-blind clinical trial evaluating the long-term effectiveness and safety of phentermine for weight management.
The 870 participants were randomized 1:1 to receive either phentermine (up to 24 mg daily) plus lifestyle-based therapy or placebo plus lifestyle-based therapy over a 24-month intervention period. The study’s co-primary endpoints were percent weight loss and change in systolic blood pressure at 24 months. The trial was investigator-initiated and funded by the National Heart, Lung, and Blood Institute with study medication donated by KVK Tech Pharmaceuticals.
According to Dr. Pajewski, a key strength of LEAP was its emphasis on real-world applicability. Eligibility criteria were intentionally broad to maximize external validity and reflect patients typically seen in primary care settings. Participants received a structured lifestyle intervention, including a 24-month Weight Watchers membership, digital self-monitoring tools, and ongoing clinician support.
“We tried to do something that was pragmatic, designed around what’s available in primary care,” Dr. Pajewski said.
Top-Line Results

The headline findings of the LEAP trial were presented by Kristina Lewis, MD, MPH, SM, associate professor at Wake Forest University School of Medicine and Advocate Health, who reported that participants assigned to phentermine experienced significantly greater weight loss than those receiving placebo throughout the 24-month study.
She emphasized that the results were generated from the intention-to-treat population and incorporated the realities of clinical practice, including treatment interruptions, medication discontinuation, and the use of other obesity therapies during follow-up.
“Patients assigned to take phentermine had greater weight loss than placebo throughout two years of follow-up in intention-to-treat analysis,” she said, noting that the findings provide a practical view of what clinicians might expect in real-world settings rather than under idealized study conditions
Weight loss with phentermine reached approximately 8% during the first year and remained above 6% at two years, despite some expected regain over time. More than half of participants receiving phentermine maintained at least 5% weight loss at 24 months, while roughly one-third achieved reductions greater than 10%.
Dr. Lewis highlighted one unexpected observation that caught the investigators’ attention. “Our placebo group blew us away in terms of their weight loss,” she said, noting that participants in the control arm performed better than anticipated and maintained weight loss throughout follow-up. These findings suggest that the structured lifestyle intervention embedded within LEAP was highly effective, making the demonstrated benefit of phentermine all the more noteworthy.
Equally important were the trial’s safety results, particularly regarding cardiovascular risk. Despite longstanding concerns surrounding sympathomimetic medications, LEAP found no significant difference in systolic blood pressure between treatment groups over two years. “We were very reassured to see that phentermine did not raise systolic blood pressure,” she told attendees. Average blood pressure remained stable throughout follow-up, while major adverse cardiovascular events were rare.
The investigators observed a modest increase in resting heart rate consistent with phentermine’s mechanism of action, but average heart rates remained below 80 beats per minute throughout the study. Meanwhile, incident hypertension diagnoses were uncommon, and serious adverse events occurred at similar rates in both study arms.
Dr. Lewis also addressed the longstanding concern of dependence. “Phentermine did not produce signs of drug dependence, and it was generally well tolerated and safe,” she said. Common adverse effects such as dry mouth, constipation, and insomnia were reported primarily during the first month of treatment and became uncommon later in the study.
LEAP In Practice

Kimberly Gudzune, MD, MPH, FTOS, a research consultant at Wake Forest University School of Medicine and Advocate Health and affiliate faculty member at Johns Hopkins Bloomberg School of Public Health, examined what the LEAP trial means for everyday clinical practice and whether its findings finally resolve the longstanding uncertainty surrounding long-term phentermine use.
Reviewing the trial’s design, Dr. Gudzune emphasized its real-world applicability. Participants reflected patients commonly encountered in primary care, and the intervention incorporated pragmatic elements including flexible phentermine dosing, digital lifestyle support, and weight-focused clinical follow-up. She stressed that LEAP was “very much an effectiveness trial, not an efficacy trial.”
Placing the results in the broader obesity-treatment landscape, Dr. Gudzune observed that phentermine’s weight-reduction efficacy may not rival that of newer GLP-1–based therapies, but remains clinically meaningful, particularly given its low cost and accessibility. She highlighted that approximately two-thirds of participants achieved at least 5% weight reduction, one-third achieved 10% weight loss, and one in five achieved 15% weight loss at one year.
She underscored the favorable safety findings, noting, “I think there are more advantages than disadvantages here. So overall, I think that this is a tool that should be in our toolbox.”
Looking ahead, Dr. Gudzune suggested that the LEAP findings may influence future obesity treatment guidelines, stimulate research on combination and step-therapy approaches, and prompt discussions about FDA labeling, DEA scheduling requirements, and broader insurance coverage.









